UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~July~~September 2621, 2010

SINOBIOPHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

Nevada	333-144910	26-3002371
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

8 Zhong Tian Road, Nantong City, Jiangsu Province, People’s Republic of China 226009 (Address of Principal Executive Offices)

Registrant's telephone number, including area code: ~~011 -~~ (86) 51-385328336

Copies to:

Gregory Sichenzia, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Phone: (212) 930-9700

Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ 1~~.01 Entry into a Material Definitive Agreement.~~

OnItem ~~July 26, 2010, Sinobiopharma, Inc~~2.’s02 Results (the “Company’s”) wholly-owned subsidiary, DongYing (Jiangsu) Pharmaceutical Co., Ltd. (“DongYing”), entered into a Cooperation Agreement (the “Agreement”) with Jiangsu LianHuan Pharmaceuticals Co., Ltd. (“LianHuan”) for the co-development, manufacture, and marketing of ~~the~~Operations ~~drug Eplerenone, a therapeutic agent formulated to treat high blood pressure~~ and ~~vascular~~Financial ~~diseases, and its tablet and capsule forms (the “Eplerenone”)~~Condition.

~~Clinical~~On ~~trial~~September ~~certificates~~21, ~~for~~2010, ~~Eplerenone~~Sinobiopharma, ~~are~~Inc., ~~currently~~a ~~owned~~Nevada bycorporation ~~DongYing. According to~~ (the ~~Agreement~~“Company”), ~~LianHuan~~announced ~~shall~~its beresults ~~responsible~~of operations for ~~all~~the ~~fees~~fiscal ~~and~~year ~~expenses~~ended ~~incurred~~May in31, ~~the clinical trials~~2010. ~~Following~~A ~~the~~copy ~~completion~~ of ~~clinical trials, LianHuan and DongYing shall jointly complete and submit~~ the ~~drug~~related ~~production~~press ~~application. Once~~release ~~production approval for Eplerenone~~ is ~~obtained,~~being ~~LianHuan~~filed ~~and~~as ~~DongYing~~Exhibit ~~shall jointly own the new drug production certificate for Eplerenone~~99.1 ~~LianHuan~~to ~~shall~~this beForm ~~responsible~~8-K ~~for the manufacture of Eplerenone~~ and ~~its~~is ~~tablet~~incorporated ~~form,~~herein ~~though~~by ~~DongYing~~reference ~~retains~~in ~~the~~its ~~option to produce Eplerenone capsules~~entirety. ~~The net profit from the sales of Eplerenone shall be apportioned as 60 percent to DongYing and 40 percent to LianHuan.~~

The ~~foregoing~~information ~~description~~in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the ~~Agreement~~Securities isExchange aAct ~~summary~~of ~~and~~1934, isas ~~not~~amended ~~complete.~~(the A“Exchange ~~copy~~Act”), or incorporated subject to the liabilities of that section or Sections 11 and 12(a)(2) of the ~~Cooperation~~Securities ~~Agreement~~Act isof ~~filed~~1933, as ~~Exhibit~~amended ~~10.1~~(the to“Securities Act”), and shall not be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, ~~this~~whether ~~report~~made before or after the date hereof, regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events

On August 10, 2010, the Company issued a press release to announce the Agreement with LianHuan. A copy of the press release that discusses this matter is filed as Exhibit 99.1 to, and incorporated by reference in, this report.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
	10.1 Cooperation Agreement, dated July 26, 2010.
	99.1 Press Release, dated August 10, 2010, issued by Sinobiopharma, Inc.

(d) Exhibits.

99.1

Press release dated September 21, 2010, issued by Sinobiopharma, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 10, 2010

	Date: September 21, 2010

	SINOBIOPHARMA, INC.

	By:	/s/ Lequn Huang
		Lequn Huang
		Chief Executive Officer

SINOBIOPHARMA, INC.

By:/s/ Xinjie Mu

Xinjie Mu

Chief Financial Officer

Filing Compare · Sinobiopharma, Inc.